Oral physostigmine treatment of patients with Alzheimer's disease.
Oral physostigmine treatment of patients with Alzheimer's disease.
复制标题
口服毒扁豆碱治疗阿尔茨海默病患者。
DOI：
10.1176/ajp.142.1.28
复制
发表时间：
1985
期刊：
影响因子：
--
通讯作者：
Davis,KL
中科院分区：
文献类型：
--
作者：
Mohs,RC;Davis,BM;Johns,CA;Mathe,AA;Greenwald,BS;Horvath,TB;Davis,KL
12例阿尔茨海默病患者每2小时口服芥子碱0.0、0.5、1.0、1.5和2.0 mg，持续3-5天；用阿尔茨海默病评估量表评估每次给药后的症状。然后重新给药安慰剂和与最不严重症状相关的剂量，各3-5天。在完成研究的10名患者中，3名患者在两个阶段的最高药量均有临床显着改善，4名患者在两个阶段均略有改善，3名患者对药量的反应不一致。在一项睡眠研究中获得的皮质醇测量表明，服药后症状改善的患者是那些口服服药后中枢胆碱能活性增强的患者。
Twelve patients with Alzheimer's disease received 0.0, 0.5, 1.0, 1.5, and 2.0 mg of oral physostigmine every 2 hours for 3-5 days; symptoms after each dose were assessed with the Alzheimer's Disease Assessment Scale. Placebo and the dose associated with the least severe symptoms were then readministered for 3-5 days each. Of the 10 patients who completed the study, three showed clinically significant improvement on the highest physostigmine dose in both phases, four more were marginally improved in both phases, and three had inconsistent responses to physostigmine. Cortisol measures obtained during a sleep study suggest that patients whose symptoms improved on physostigmine were those in whom oral physostigmine enhanced central cholinergic activity.